Expression of matriptase and clinical outcome of human endometrial cancer

Anticancer Research

Volumn 29, Issue 5, 2009, Pages 1685-1690

  Nakamura, Keiichiro ^a   Hongo, Atsushi ^a   Kodama, Junichi ^a   Abarzua, Fernando ^a   Nasu, Yasutomo ^a   Kumon, Hiromi ^a   Hiramatsu, Yuji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Endometrial cancer; Matriptase; Prognostic significance

Indexed keywords

MATRIPTASE;

ARTICLE; CANCER INVASION; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; SERINE ENDOPEPTIDASES; TREATMENT OUTCOME;

EID: 67650073220     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
2. Parazzini F, La Vecchia C, Bocciolone L and Franceschi S: The epidemiology of endometrial cancer. Gynecol Oncol 41: 1-16, 1991.
3. Annual Report of Oncology Committee of Japan Society of Obstetrics and Gynecology, Tokyo, Japan 2008.
4. Chang C and Werb Z: The many faces of metalloproteases: Cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 11: 37-43, 2001. (Pubitemid 33001442)
5. Del Rosso M, Fibbi G, Pucci M, D'Alessio S, Del Rosso A, Magnelli L and Chiarugi V: Multiple pathways of cell invasion are regulated by multiple families of serine proteases. Clin Exp Metastasis 19: 193-207, 2002. (Pubitemid 34553521)
6. Lin CY, Anders J, Johnson M, Sang QA and Dickson RB: Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J Biol Chem 274: 18231-18236, 1999. (Pubitemid 129519220)
7. Takeuchi T, Shuman MA and Craik CS: Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci USA 96: 11054-11061, 1999. (Pubitemid 29487326)
8. Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR and Craik CS: Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 275: 26333-26342, 2000. (Pubitemid 30676685)
9. Lee SL, Dickson RB and Lin CY: Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 275: 36720-36725, 2000. (Pubitemid 32002078)
10. Kang JY, Dolled-Filhart M, Ocal IT, Singh B, Lin CY, Dickson RB, Rimm DL and Camp RL: Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 63: 1101-1105, 2003. (Pubitemid 36278444)
11. Lee JW, Yong Song S, Choi JJ, Lee SJ, Kim BG, Park CS, Lee JH, Lin CY, Dickson RB and Bae DS: Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia. Hum Pathol 36: 626-633, 2005. (Pubitemid 40922568)
12. Tanimoto H, Shigemasa K, Tian X, Gu L, Beard JB, Sawasaki T and O'Brien TJ: Transmembrane serine protease TADG-15 (ST14/Matriptase/MT-SP1): expression and prognostic value in ovarian cancer. Br J Cancer 92: 278-283, 2005. (Pubitemid 40343141)
13. Oberst MD, Johnson MD, Dickson RB, Lin CY, Singh B, Stewart M, Williams A, al-Nafussi A, Smyth JF, Gabra H and Sellar GC: Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin Cancer Res 8: 1101-1107, 2002. (Pubitemid 35177362)
14. Riddick AC, Shukla CJ, Pennington CJ, Bass R, Nuttall RK, Hogan A, Sethia KK, Ellis V, Collins AT, Maitiand NJ, Ball RY and Edwards DR: Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br J Cancer 92: 2171-2180, 2005. (Pubitemid 40966253)
15. Berchuck A, Rodriguez G, Kinney RB, Soper JT, Dodge RK, Clarke-Pearson DL and Bast RC Jr: Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 164: 15-21, 1991.
16. Borst MP, Baker VV, Dixon D, Hatch KD, Shingleton HM, Miller DM: Oncogene alterations in endometrial carcinoma. Gynecol Oncol 38: 364-366, 1990.
17. Okamoto A, Sameshima Y, Yamada Y, Teshima S, Terashima Y, Terada M and Yokota J: Allelic loss on chromosome 17p and p53 mutations in human endometrial carcinoma of the uterus. Cancer Res 51: 5632-5635, 1991.
18. Oberst MD, Singh B, Ozdemirli M, Dickson RB, Johnson MD and Lin CY: Characterization of matriptase expression in normal human tissues. J Histochem Cytochem 51: 1017-1025, 2003. (Pubitemid 36919979)
19. List K, Szabo R, Molinolo A, Nielsen BS and Bugge TH: Delineation of matriptase protein expression by enzymatic gene trapping suggests diverging roles in barrier function, hair formation, and squamous cell carcinogenesis. Am J Pathol 168: 1513-1525, 2006.
20. Zeng L, Cao J and Zhang X: Expression of serine protease SNC19/matriptase and its inhibitor hepatocyte growth factor activator inhibitor type 1 in normal and malignant tissues of gastrointestinal tract. World J Gastroenterol 11: 6202-6207, 2005. (Pubitemid 43085066)
21. Parr C, Watkins G, Mansel RE and Jiang WG: The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res 10: 202-211, 2004. (Pubitemid 38114181)
22. Kang JY, Dolled-Filhart M, Ocal IT, Singh B, Lin CY, Dickson RB, Rimm DL and Camp RL: Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 63: 1101-1105, 2003. (Pubitemid 36278444)